Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

4-(4-bromophenyl)-2,3-dihydro-N,3-bis(3,4,5-trimethoxyphenyl)-2-oxoidmi-dazole-1-carboxamide MeSH Supplementary Concept Data 2025


MeSH Supplementary
4-(4-bromophenyl)-2,3-dihydro-N,3-bis(3,4,5-trimethoxyphenyl)-2-oxoidmi-dazole-1-carboxamide
Unique ID
C517487
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C517487
Entry Term(s)
MZ3 cpd
Registry Numbers
0
Heading Mapped to
*Imidazoles
Frequency
3
Note
MZ3 is a potent compound against leukemia cell lines both in vitro and in vivo, and the mitochondrial pathway mediated by Bcl-2 protein family and MAPKs might be involved in signaling MZ3-induced apoptosis; structure in first source
Source
Cancer Chemother Pharmacol. 2007 Feb;59(3):397-405
Date of Entry
2007/02/27
Revision Date
2007/02/27
4-(4-bromophenyl)-2,3-dihydro-N,3-bis(3,4,5-trimethoxyphenyl)-2-oxoidmi-dazole-1-carboxamide Preferred
page delivered in 0.005s